Ciltacabtagene Autoleucel, an Anti–B-cell Maturation Antigen Chimeric Antigen Receptor T-Cell Therapy, for Relapsed/Refractory Multiple Myeloma: CARTITUDE-1 2-Year Follow-Up
Thomas G. Martin(University of California San Francisco Medical Center), Sundar Jagannath(Mount Sinai Hospital), Saad Z. Usmani(Memorial Sloan Kettering Cancer Center), Yunsi Olyslager(Janssen (Belgium)), Deepu Madduri(Johnson & Johnson (United States)), Enrique Zudaire(Centro de Investigación del Cáncer), A. Keith Stewart(Princess Margaret Hospital), Mounzer Agha(Dana-Farber Cancer Institute), Myo Htut(City Of Hope National Medical Center), Adam D. Cohen(Penn Center for AIDS Research), Parameswaran Hari(Medical College of Wisconsin), Alexander M. Lesokhin(Memorial Sloan Kettering Cancer Center), Nikhil C. Munshi(Dana-Farber Cancer Institute), Lida Pacaud(Centro de Investigación del Cáncer), Jesús G. Berdeja(Tennessee Oncology), Abhinav Deol(Wayne State University), David Avigan(Beth Israel Deaconess Medical Center), Elizabeth O’Donnell(Harvard University), Arnob Banerjee(Johnson & Johnson (United States)), Andrzej Jakubowiak(University of Chicago Medical Center), Jordan M. Schecter(Centro de Investigación del Cáncer), William Deraedt(Janssen (Belgium)), Yi Lin, Tzu‐Min Yeh(Centro de Investigación del Cáncer), Alicia J. Allred(Queen's University Belfast), Changwei Zhou(Harbin Medical University), Carolyn C. Jackson(Centro de Investigación del Cáncer)
Cited by 647
Related Papers
Signatures of mutational processes in human cancer
|Nature|2013|10.1k
Nivolumab plus Ipilimumab in Advanced Melanoma
|New England Journal of Medicine|2013|4.2k
An inflammatory cytokine signature predicts COVID-19 severity and survival
|Nature Medicine|2020|2.7k
Immunologic Correlates of the Abscopal Effect in a Patient with Melanoma
|New England Journal of Medicine|2012|2.1k
Anti-BCMA CAR T-Cell Therapy bb2121 in Relapsed or Refractory Multiple Myeloma
|New England Journal of Medicine|2019|1.7k